ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Recursion, a company that uses machine learning for drug discovery, is partnering with Roche and its subsidiary Genentech to identify novel drug targets and develop drugs against them. The firms will rely heavily on single-cell data for neuroscience and cancer indications. The partnership could include up to 40 drug programs. Roche will pay Recursion $150 million up front and potentially more than $300 million in milestone payments for each program.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter